A RESPONSE TO: "COST-EFFECTIVENESS OF ORAL SEMAGLUTIDE ADDED TO CURRENT ANTIHYPERGLYCEMIC TREATMENT FOR TYPE 2 DIABETES"

J Manag Care Spec Pharm. 2021 Aug;27(8):1140-1141. doi: 10.18553/jmcp.2021.27.8.1140.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Cost-Benefit Analysis
  • Diabetes Mellitus, Type 2* / drug therapy
  • Glucagon-Like Peptides
  • Humans
  • Hypoglycemic Agents* / therapeutic use

Substances

  • Hypoglycemic Agents
  • semaglutide
  • Glucagon-Like Peptides